Benitec Biopharma Inc.
For the period ended Jun 30, 2026. Filed Sep 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 14, 2026
BNTC$9.28-6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year Ended | ||
|---|---|---|
| June 30, | ||
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | 23,388 | 18,332 |
| General and administrative | 27,804 | 23,433 |
| Total operating expenses | 51,192 | 41,765 |
| Loss from operations | (51,192) | (41,765) |
| Other income (loss): | ||
| Foreign currency transaction gain (loss) | 120 | (71) |
| Interest income, net | 5,569 | 3,286 |
| Other expense, net | (43) | (131) |
| Gain on extinguishment of liabilities | — | 764 |
| Total other income, net | 5,646 | 3,848 |
| Net loss | $(45,546) | $(37,917) |
| Other comprehensive income: | ||
| Unrealized foreign currency translation gain (loss) | (124) | 53 |
| Total other comprehensive income (loss) | (124) | 53 |
| Total comprehensive loss | $(45,670) | $(37,864) |
| Net loss | $(45,546) | $(37,917) |
| Net loss attributable to common shareholders | $(45,546) | $(37,917) |
| Net loss per share: | ||
| Basic and diluted | $(0.98) | $(1.05) |
| Weighted average number of shares outstanding: | ||
| Basic and diluted | 46,558,162 | 36,209,271 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.